These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26002398)

  • 1. QT Prolongation and Oncology Drug Development.
    Fradley MG; Moslehi J
    Card Electrophysiol Clin; 2015 Jun; 7(2):341-55. PubMed ID: 26002398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
    Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
    Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.
    Porta-Sánchez A; Gilbert C; Spears D; Amir E; Chan J; Nanthakumar K; Thavendiranathan P
    J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29217664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular mechanisms underlying the long QT syndrome.
    Antzelevitch C; Shimizu W
    Curr Opin Cardiol; 2002 Jan; 17(1):43-51. PubMed ID: 11790933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approach to initiating QT-prolonging oncology drugs in the ambulatory setting.
    de Lemos ML; Kung C; Kletas V; Badry N; Kang I
    J Oncol Pharm Pract; 2019 Jan; 25(1):198-204. PubMed ID: 29298624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics.
    Chandrasekhar S; Fradley MG
    Curr Treat Options Oncol; 2019 May; 20(7):55. PubMed ID: 31129799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-induced long QT syndrome and torsade de pointes.
    Morissette P; Hreiche R; Turgeon J
    Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Takotsubo cardiomyopathy as a potential cause of long QT syndrome and torsades de pointes.
    Ghosh S; Apte P; Maroz N; Broor A; Zeineh N; Khan IA
    Int J Cardiol; 2009 Aug; 136(2):225-7. PubMed ID: 18617280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV protease inhibitors induced prolongation of the QT Interval: electrophysiology and clinical implications.
    Singh M; Arora R; Jawad E
    Am J Ther; 2010; 17(6):e193-201. PubMed ID: 19636247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart.
    Bottino D; Penland RC; stamps A; Traebert M; Dumotier B; Georgiva A; Helmlinger G; Lett GS
    Prog Biophys Mol Biol; 2006; 90(1-3):414-43. PubMed ID: 16321428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Torsades de pointes and long QT syndromes.
    Janeira LF
    Am Fam Physician; 1995 Oct; 52(5):1447-53. PubMed ID: 7572567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced long QT and torsade de pointes: recent advances.
    Kannankeril PJ; Roden DM
    Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QT interval measurement in ventricular pacing: Implications for assessment of drug effects and pro-arrhythmia risk.
    Schurr JW; Grewal PK; Fan R; Rashba E
    J Electrocardiol; 2022; 70():13-18. PubMed ID: 34826635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofloxacin induced acquired long QT syndrome in a patient under class III antiarrhythmic therapy.
    Keivanidou A; Arnaoutoglou C; Krommydas A; Papanikolaou G; Tsiptses K; Chrisopoulos C; Kirpizidis C
    Cardiol J; 2009; 16(2):172-4. PubMed ID: 19387967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
    Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
    Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes.
    Isbister GK; Balit CR; Macleod D; Duffull SB
    J Clin Psychopharmacol; 2010 Aug; 30(4):391-5. PubMed ID: 20531221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.